samedan logo

home > ebr > spring 2021 > beyond cold
European Biopharmaceutical Review

Beyond Cold

Without a doubt, 2020 was an unusual year. The SARSCoV-2 pandemic reshaped how we work, live, learn, and interact at every level. The global response, however, was unprecedented. The imperative to contain the virus pushed the vaccine industry into the public spotlight and the outcome was disruptive: a new generation of vaccines emerged that has redefined immunisation strategies.

A New Era in Vaccine Storage

Vaccines based on novel mRNA and viral vector technologies are in line to bring the world back to normalcy. Developed, tested, and approved in record time, these vaccines have changed how industry produces, manages, and – above all – moves immunisations through the cold chain from manufacturing sites to anxiously waiting end users. Within the span of just 11 months, the transport and storage of vaccines at -70°C became a global priority. Before last year, ultra-low temperature (ULT) had only been used for the highly localised delivery of trial vaccines during Ebola outbreaks.

Until now, most vaccines were commonly stored between 2°C and 8°C worldwide. Consequently, the existing cold chain infrastructure built on standard refrigerators and freezers was insufficient to accommodate these new ULT storage needs. In anticipation and support of these new vaccine modes, and facing the largest immunisation campaign in human history, cold chain infrastructure is expanding to reach far below sub-zero temperatures and adding storage facilities to accommodate massive numbers of doses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Dr Alex Esmon is Senior Director/General Manager for Cold Storage at the laboratory products division of Thermo Fisher Scientific. With a PhD in Molecular Biology from the University of Missouri, Columbia, US, Dr Esmon has over 13 years of experience in industry and has overseen almost all aspects of managing products for cold storage and cryopreservation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Rousselot® Biomedical Announces the Launch of Quali-Pure HGP 2000

Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement